“Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s650. doi:10.25251/8xwzce61.